gala send-off for the General Counsel, through the aggressive public statements of the Dean of the Medical School and the relentless public relations campaign for Charles Schulz, it has become plain that no plans for change are being contemplated. Just the opposite, in fact: the President of the university has made it clear that he wants more clinical trials and more partnerships with industry.
Given our scandal-plagued history, this is not really a surprise. Perhaps the petition calling for an investigation will eventually have an effect. In the meantime, however, the very same rules and oversight system that failed Dan Markingson will continue to fail other vulnerable patients.